Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial

Strong potential for POLB 001 to be a blockbuster treatment for severe influenza

Key Highlights

·      POLB 001 resulted in a highly significant reduction in p38 MAP kinase driven cytokines

·      POLB 001 treatment exhibited a marked reduction in multiple markers of systemic and local inflammation compared with placebo

·    Trial results demonstrate expected utility in severe influenza and other acute inflammatory conditions

Read more